世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

世界の点頭てんかん治療薬市場 2017-2021年

Global Infantile Spasms Therapeutics Market 2017-2021

 

出版社 出版年月電子版価格 ページ数
TechNavio
テクナビオ
2016年12月US$3,500
シングルユーザライセンス
73

サマリー

このレポートは世界の点頭てんかん治療薬市場を調査したTechNavio社の調査報告書です。

Report Details

About Infantile Spasms Therapeutics

An infantile spasm is a particular type of seizure found in an epilepsy syndrome of infancy and childhood. It is also known as a West syndrome. The onset of infantile spasm is usually found in the first year of life between four months and eight months of age. The condition constitutes 2% of childhood epilepsies and 25% of epilepsies with onset in the first year of life. There are around 2,000-4,000 new cases observed in the US each year. The overall long-term prognosis for infantile spasms patients is poor. It has been found that 50%-70% of infantile spasms patients develop other seizure types and 18%-50% will develop Lennox-Gastaut syndrome (LGS) or other forms of symptomatic generalized epilepsy.

Technavio’s analysts forecast the global infantile spasms therapuetics market to grow at a CAGR of 10.16% during the period 2017-2021.

Covered in this report
The report covers the present scenario and the growth prospects of the global thoracic surgery market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of infantile spasms therapuetics.

The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA

Technavio's report, Global Infantile Spasms Therapeutics Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
- H. Lundbeck
- Mallinckrodt Pharmaceuticals
- INSYS Therapeutics

Other prominent vendors
- Anavex Life Sciences
- Catalyst Pharmaceuticals
- GW Pharmaceuticals
- ORPHELIA Pharma
- Retrophin
- Valerion Therapeutics

Market driver
- Major drugs launch expected in 2017-2021
- For a full, detailed list, view our report

Market challenge
- Growing usage of seizure management devices, a threat to drug therapies
- For a full, detailed list, view our report

Market trend
- Development of devices and smartphone apps to detect seizures and track medications
- For a full, detailed list, view our report

Key questions answered in this report
- What will the market size be in 2021 and what will the growth rate be-
- What are the key market trends-
- What is driving this market-
- What are the challenges to market growth-
- Who are the key vendors in this market space-
- What are the market opportunities and threats faced by the key vendors-
- What are the strengths and weaknesses of the key vendors-

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.






目次

Table of Contents
PART 01: Executive summary
PART 02: Scope of the report
- Market overview
- Top-vendor offerings
PART 03: Market research methodology
- Research methodology
- Economic indicators
PART 04: Introduction
- Key market highlights
PART 05: Infantile spasm: Overview
PART 06: Market landscape
- Global infantile spasms therapeutics market
- Five forces analysis
PART 07: Market segmentation by dosage form
- Solid
- Liquid
PART 08: Market segmentation by ROA
- Oral
- Parenteral
PART 09: Geographical segmentation
- Infantile spasms therapeutics market in Americas
- Infantile spasms therapeutics market in EMEA
- Infantile spasms therapeutics market in APAC
PART 10: Market drivers
- Major drugs launch expected in 2017-2021
- Growing scientific advancements in diagnostics
- Special regulatory designations
PART 11: Impact of drivers
PART 12: Market challenges
- Growing usage of seizure management devices, a threat to drug therapies
- Limited patient population
- Moderate pipeline
PART 13: Impact of drivers and challenges
PART 14: Market trends
- Development of devices and smartphone apps to detect seizures and track medications
- Alternate drugs fill the gap
- Reformulation of marketed drugs
PART 15: Vendor landscape
- Competitive scenario
- Other prominent vendors
PART 16: Key vendor analysis
- H. Lundbeck
- Mallinckrodt Pharmaceuticals
- INSYS Therapeutics
PART 17: Appendix
- List of abbreviations
PART 18: Explore Technavio
List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Snapshot of global infantile spasms therapeutics market 2016
Exhibit 03: Market overview of global infantile spasms therapeutics market
Exhibit 04: Opportunity analysis in developed and emerging markets
Exhibit 05: Global infantile spasm therapeutics market 2016-2021 ($ millions)
Exhibit 06: Approved infantile spasms therapeutics
Exhibit 07: Key customer segments of global infantile spasms therapeutics market
Exhibit 08: Five forces analysis
Exhibit 09: Segmentation of global infantile spasms therapeutics market by dosage form
Exhibit 10: Segmentation of global infantile spasms therapeutics market by ROA
Exhibit 11: Market share of global infantile spasms therapeutics market by ROA
Exhibit 12: Snapshot of global infantile spasms therapeutics market by geography
Exhibit 13: Global infantile spasms therapeutics market segmentation by geography 2016-2021 ($ millions)
Exhibit 14: Overview of infantile spasms therapeutics disease market in Americas
Exhibit 15: Market scenario in Americas
Exhibit 16: Healthcare system in US: Before and after reforms in ACA
Exhibit 17: Orphan drug development and regulatory challenges in America
Exhibit 18: Incentives provided for orphan drugs by US regulation
Exhibit 19: Infantile spasms therapeutics disease market in Americas 2016-2021 ($ millions)
Exhibit 20: Overview of infantile spasms therapeutics market in EMEA
Exhibit 21: Percentage share of epilepsy drugs market in EMEA by geography 2015
Exhibit 22: Market scenario in EMEA
Exhibit 23: Incentives provided for orphan drugs by EU regulation
Exhibit 24: Infantile spasms therapeutics market in EMEA 2016-2021 ($ millions)
Exhibit 25: Overview of infantile spasms market in APAC
Exhibit 26: Market scenario in APAC
Exhibit 27: Incentives provided for orphan drugs by Japanese regulation
Exhibit 28: Incentives provided for orphan drugs by Australian regulation
Exhibit 29: Infantile spasms therapeutics market in APAC 2016-2021 ($ millions)
Exhibit 30: CP-115 target indications
Exhibit 31: Clinical trial information for cannabidiol
Exhibit 32: Impact of drivers
Exhibit 33: Pipeline for infantile spasms therapeutics market
Exhibit 34: Pipeline molecules being developed for the treatment of infantile spasms disease
Exhibit 35: Impact of drivers and challenges
Exhibit 36: Impact of trends in global infantile spasms therapeutics market
Exhibit 37: Competitive structure analysis of global infantile spasm therapeutics market 2016
Exhibit 38: Geographical presence of key vendors
Exhibit 39: H. Lundbeck: Key highlights
Exhibit 40: H. Lundbeck: Strength assessment
Exhibit 41: H. Lundbeck: Strategy assessment
Exhibit 42: H. Lundbeck: Opportunity assessment
Exhibit 43: Mallinckrodt Pharmaceuticals: Profile
Exhibit 44: Mallinckrodt Pharmaceuticals: Strength assessment
Exhibit 45: Mallinckrodt Pharmaceuticals: Strategy assessment
Exhibit 46: Mallinckrodt Pharmaceuticals: Opportunity assessment
Exhibit 47: INSYS Therapeutics: Key highlights
Exhibit 48: INSYS Therapeutics: Strength assessment
Exhibit 49: INSYS Therapeutics: Strategy assessment
Exhibit 50: INSYS Therapeutics: Opportunity assessment

 

ページTOPに戻る

あなたが最近チェックしたレポート一覧

  • 最近チェックしたレポートはありません。

お問合は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのお問合せはこちらのフォームから承ります

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

<無料>メルマガに登録する

 

 

ページTOPに戻る